What is RDA™
RDA™ will provide physicians with an evaluation of how patients are responding to cancer treatment.
RNA Disruption Assay (RDA™) is a cancer diagnostic platform measuring tumor response early in cancer treatment. If the cancer drugs are likely to provide the patient with a benefit, the physician and patient can continue with confidence. If the cancer drugs are highly unlikely to benefit the patient, physicians may consider alternate treatments. For patients, this means avoiding harmful side effects and an opportunity to improve outcomes.
How does RDA™ work?
A needle biopsy is taken during cancer treatment to determine the degree of ribosomal RNA (rRNA) disruption. The disruption of rRNA is a biomarker of impending cell death. If the cancer drugs are working the rRNA will be highly disrupted. If the cancer drugs are not working the rRNA will be intact.
RDA™ will offer significant benefits for patients, physicians and healthcare systems.
- Patients avoid harmful side effects and can be considered for alternate treatments that may improve their survival.
- Physicians have an objective tool to personalize treatment for each patient.
- Healthcare payers avoid the substantial costs of a treatment that isn’t working.